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Abstract
Rationale Within the basal ganglia, the subthalamic nucleus
(STN) is the only glutamatergic structure and occupies a
central position in the indirect pathway. In rat, the STN re-
ceives serotonergic input from the dorsal raphe nucleus and
expresses serotonergic receptors.
Objective This study examined the consequences of seroto-
nergic neurotransmission modulation on STN neuron activity.
Methods In vivo single-unit extracellular recordings, HPLC
determination, and rotarod and bar test were performed in
control, 4-chloro-DL-phenylalanine methyl ester
hydrochloride- (pCPA, a serotonin synthesis inhibitor) and
chronically fluoxetine-treated rats.
Results The pCPA treatment and the administration of sero-
tonin (5-HT) receptor antagonists increased number of burst-
ing neurons in the STN. The systemic administration of the 5-
HT1A agonist, 8-OH-DPAT, decreased the firing rate and
increased the coefficient of variation of STN neurons in
pCPA-treated rats but not in control animals. Additionally,
microinjection of 8-OH-DPAT into the STN reduced the firing
rate of STN neurons, while microinjection of the 5-HT2C
agonist, Ro 60-0175, increased the firing rate in both control
and fluoxetine-treated animals. Finally, the fluoxetine chal-
lenge increased the firing rate of STN neurons in fluoxetine-
treated rats and induced catalepsy.
Conclusions Our results indicate that the depletion and the
blockage of 5-HT modify STN neuron firing pattern. STN
neuron activity is under the control of 5-HT1A and 5-HT2C
receptors located both inside and outside the STN. Finally,
fluoxetine increases STN neuron activity in chronically
fluoxetine-treated rats, which may explain the role of this
nucleus in fluoxetine-induced extrapyramidal side effects.
Keywords pCPA . Subthalamic nucleus . Serotonin .













The serotonergic system is widely distributed through the
brain and modulates multiple central nervous system func-
tions such as motor activity (Benarroch 2009). Several clinical
reports have highlighted that the chronic treatment with
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selective serotonin (5-HT) reuptake inhibitors (SSRIs), such
as fluoxetine, can induce extrapyramidal side effects (e.g.,
tardive dyskinesia or parkinsonism), akathisia and/or dystonia
(Bilen et al. 2008; Leo 1996). Studies performed in neonatal
rats have also shown that fluoxetine treatment reduces loco-
motor activity (Lee 2012). These side effects may occur
because chronic 5-HT transporter blockage alters the
functionality of the basal ganglia (BG) (Morelli et al.
2011). In fact, the BG receive serotonergic innervation
arising mainly from the dorsal raphe nucleus (Di Matteo
et al. 2008; Liu et al. 2007).
The BG form a highly organized network that connects the
thalamus with the cortex and plays an important role in the
regulation of motor behavior. In this circuit, the subthalamic
nucleus (STN) is the sole glutamatergic nucleus and it exerts
the principal glutamate-mediate excitatory effect upon the
output structures of the BG. Dysregulation of STN neuron
activity has been related to motor disturbances (Crossman
2000; Obeso et al. 2000). As other BG nuclei, the STN
receives serotonergic innervation and contains 5-HT and its
metabolite, 5-hydroxy-indolacetic acid (5-HIAA) (Lavoie and
Parent 1990; Palkovits et al. 1974; Saavedra 1977).
Expression of 5-HT1A, 5-HT2C, and 5-HT4 mRNA and bind-
ing sites have also been shown in STN cells (Eberle-Wang
et al. 1997; Grossman et al. 1993; Maroteaux et al. 1992;
Pazos et al. 1985; Pazos and Palacios 1985; Pompeiano et al.
1992; Waeber et al. 1996). Moreover, 5-HT1B/D receptors are
present in the terminals of neurons that project to the STN
from the motor cortex and the external segment of the globus
pallidus (Hannon and Hoyer 2008; Hoyer et al. 2002; Sari
et al. 1999).
Using in vitro recording techniques, it has been shown that
5-HT increases the spontaneous firing rate of STN neurons via
5-HT2C and 5-HT4 receptors (Flores et al. 1995; Shen et al.
2007; Stanford et al. 2005; Xiang et al. 2005) and produces the
opposite effect through 5-HT1A receptors (Shen et al. 2007;
Stanford et al. 2005). On the other hand, non-selective 5-HT1
or 5-HT2 receptor agonists microinjected into the STN cause
hyperlocomotion in rats (Belforte and Pazo 2004; Martinez-
Price and Geyer 2002), whereas a 5-HT2C agonist microinjec-
tion induces orofacial dyskinesia (De Deurwaerdere and
Chesselet 2000; Eberle-Wang et al. 1996). All these findings
reveal an interaction between the serotonergic system and the
STN. However, the effect of 5-HT neurotransmission modu-
lation or 5-HT receptor activation on STN neuron activity
in vivo is still unknown.
In the present study, we aimed to determinate the in vivo
serotonergic modulation of the electrical activity of the STN
by applying serotonergic agonists and antagonists to control,
4-chloro-DL-phenylalanine methyl ester hydrochloride
(pCPA, a 5-HT synthesis inhibitor) and fluoxetine-treated rats
and to evaluate the possible impact of fluoxetine treatment on
motor behavior and STN activity. To accomplish this, both
electrophysiological and behavioral approaches were used.
Our results show that modulation of endogenous 5-HT




Male Sprague–Dawley rats (225–325 g) were housed under a
12:12 h light:dark cycle with food and water provided ad
libitum. Every effort was made to minimize animal suffering
and to use the minimum number of animals possible.
Experimental protocols were approved by the Local Ethical
Committee for Animal Research at the University of the
Basque Country. All of the experiments were performed in
compliance with the European Community Council Directive
on “The Protection of Animals Used for Experimental and
Other Scientific Purposes” (86/609/EEC) and with Spanish
Law (RD 1201/2005) for the care and use of laboratory
animals. Four experimental groups of animals were used in
this study: pCPA-treated rats (5-HT synthesis inhibitor,
300 mg/kg, i.p., 3 days; n =43) (Ugedo et al. 1989),
fluoxetine-treated rats (SSRI, 10 mg/kg, i.p., 14 days; n =24)
(Guirado et al. 2009) and their respective vehicle-treated
control rats (n =118).
Behavioral testing
Rotarod
The rotarod test was performed to detect potential impairment
of motor performance and coordination in the rats (Dekundy
et al. 2006). Animals were pre-trained for four consecutive
days on an automated four-lane rotarod unit (Panlab, Spain)
that accelerated smoothly from 4 to 40 rpm over a period of
300 s. Every training day, three trials were performed with a
rest of 30 min between each trial to avoid fatigue. Once
animals had reached a stable baseline performance, chronic
treatment with fluoxetine or vehicle was started and testing
sessions were carried out on days 1, 5, 9, and 14 after the
beginning of the treatments. On each testing day, animals were
evaluated three times in the accelerating protocol over 300 s at
three different time points, just before, 30 and 60 min after
drug administration. The time to fall off the rod at each testing
time was recorded.
Bar test
The bar test was carried out to measure catalepsy along the
chronic treatment with fluoxetine or vehicle on days 1, 5, 9,
and 14. The latency to initiate the movement was used as
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measure of catalepsy (Dekundy et al. 2006). On each testing
day, the animals were evaluated on two consecutive trials at
three different time points just before, 30 and 60 min after
drug administration, preceding the performance on the
rotarod. On the testing trials, the animal was gently placed
with both forepaws on a 9-cm-high standard wooden bar. The
end point of catalepsy was considered when both forepaws
were removed from the bar. The maximal testing duration was
set at 120 s.
Electrophysiological procedures
The electrophysiological recording of STN neurons was per-
formed as described by Morera-Herreras et al. (2010). Rats
were anesthetized with urethane (1.2 g/kg, i.p.), and the right
jugular vein was cannulated for additional drug injections.
The rat was placed in a stereotaxic frame with its head secured
in a horizontal orientation. The recording electrode was
lowered into the right STN (relative to bregma and dura:
AP −3.6/−3.8 mm, ML −2.2/−2.7 mm, and DV −7/−8.5 mm
(Paxinos and Watson 1997). The extracellular signal from the
electrode was amplified with a high-input impedance ampli-
fier and was monitored on an oscilloscope and on an audio
monitor. All recorded STN neurons exhibited a biphasic
waveform and a pulse width of 1.0 to 1.5 ms (Hollerman
and Grace 1992). Neuronal spikes were digitized using com-
puter software (CED micro 1401 interface and Spike2 soft-
ware, Cambridge Electronic Design). The basal firing rate was
recorded for 5–10 min.
At the end of each electrophysiological experiment, a
Pontamine Sky Blue mark was deposited. The recording site
was located in brain slices by neutral red staining (Miguelez
et al. 2011), both when the administration was performed
intravenously or locally. Only cells recorded within the STN
were included in this study.
The firing parameters of STN neurons were analyzed off-
line using Spike2 software. The following parameters were
calculated: firing rate and coefficient of variation. According
to the method described by Kaneoke and Vitek (1996), three
different firing patterns could be analyzed (using the NeuronFit
program from NorayBio Informatics): (1) a tonic firing pattern,
(2) a random firing pattern, and (3) a bursting firing pattern. The
analyzed spike-trains lasted more than 120 s and contained at
least 300 spikes.
Pressure microinjection into the subthalamic nucleus
A calibrated pipette glued adjacent to a recording micropipette
(Ruiz-Ortega and Ugedo 1997) was filled either with 5 μM of
the 5-HT1A receptor agonist 8-OH-DPAT, 20 mM of the 5-
HT2C receptor agonist Ro 60-0175, 10 μM of the 5-HT1A
receptor antagonist WAY 100635, or 100 μM of the 5-HT2C
receptor antagonist SB 242084. Drugs were dissolved in
Dulbecco's buffered saline solution containing (in mM):
NaCl 136.9, KCl 2.7, NaH2PO4 8.1, KH2PO4 1.5, MgCl2
0.5, and CaCl2 0.9 (pH=7.40), with the exception of SB
242084 that was dissolved in Dulbecco's buffered saline so-
lution containing 8 % hydroxypropyl-β-cyclodextrin. Drug
injection was performed by applying pressure pulses (50–
150 ms) with a Picospritzer™ II (General Valve Corporation,
Fairfield, NJ, USA). The injected volume was measured by
monitoring the meniscus movement in a calibrated pipette.
Every pipette was calibrated so that each pulse corresponded
to the injection of 2 nl of solution.
High-performance liquid chromatography determination
For determination of 5-HT, 5-HIAA, and dopamine (DA), rats
were deeply anesthetized with urethane (1.2 g/kg, i.p.) and
decapitated. The brain was immediately extracted and the
STN was specifically dissected using a microtome with a vi-
brating blade (MicronHM650V). The tissuewas homogenized
in 0.1M perchloric acid at a concentration of 50 μg of tissue per
microliter and centrifuged (30 min, 12,500×g), and the super-
natant was spin-filtered. Finally, one aliquot corresponding to
1 mg of tissue was assessed by high-performance liquid chro-
matography with amperometric detection. The detector was
operated at 0.6 V potential between the working electrode and
the Ag/AgCl reference electrode at a sensitivity of 2 nA full-
scale deflection. The mobile phase consisted of 2 l of 0.02 M
citric acid and 1 L of 0.02 M disodium phosphate (pH=3.1),
containing 0.05 μM EDTA, 3.64 mM heptanosulphonic acid,
and 15 % methanol (v /v). The column was a 250×4.6 mm
Symmetry C18, 5 μM particle size column (Waters
Corporation). All separations were achieved isocratically at
room temperature. The flow rate was 1 ml/min.
A calibration curve was performed daily within a concen-
tration range of 0.1 to 0.9 ng of each standard per injection.
The concentrations of 5-HT, 5-HIAA, and DA in the tissue
samples were calculated by extrapolation of the samples’ peak
heights to the calibration curve.
5-HT transporter (SERT) immunohistochemistry
For determination of SERT, rats were deeply anesthetizedwith
urethane (1.2 g/kg, i.p.) and decapitated. Sections through the
prefrontal cortex, the hippocampus, and the STN containing
both hemispheres of all animals were processed at the same
time using precisely the same experimental conditions to
minimize methodological variability. For this procedure, the
brains were cut in 40-μm slices by means of a freezing
microtome (Model HM 430, Microm®, Spain), sections were
first incubated for 30 min in 30 % methanol in 0.1 M PB and
30 % hydrogen peroxide (H2O2) and then rinsed with
0.1 M PB for 5 min and placed in 1 % sodium borohydride
(Sigma-Aldrich Química, Spain) for 30 min. Afterwards, the
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sections were profusely washed with PB before rinsing in 0.1 M
Trizma base saline (TS; Sigma-Aldrich Química, Spain) for
10 min. Brain sections were then incubated in 0.5 % bovine
serum albumin (Sigma-Aldrich Química, Spain) in 0.1mTS and
0.25 % Triton X-100 (Sigma-Aldrich Química, Spain) for
30 min and right after in primary antibody (rabbit anti-SERT,
1: 2500, Immunostar, Hudson, WI, USA) for 48 h at room
temperature. The sections were rinsed in 0.1 m TS for 30 min
and incubated in 1:400 dilutions of biotinylated donkey anti-
rabbit IgG (Jackson Immunoresearch, Stratech Scientific,
Soham, UK) for 2 h at room temperature. Sections were rinsed
with 0.1 M TS for 30 min followed by incubation for 30 min in
avidin-biotin peroxidase complex (Vector Laboratories,
Peterborough, UK). The peroxidase reaction product was visu-
alized by incubation in a solution containing 0.022 % 3,3′diami-
nobenzidine (Sigma-AldrichQuímica, Spain) and 0.003%H2O2
for 10–11 min, as described previously (Rodriguez et al. 2008;
Rodriguez et al. 2009). The reaction was stopped by rinsing the
sections in 0.1MTS for 6min followed by 0.1MPB for 15min.
Brain sections were mounted onto gelatin-coated slides,
dehydrated in ascending concentration of ethanol (50, 70, 80,
90, 95, and 100 %), cleared with xylene and coverslipped.
Optical density measurement
The expression and density of SERT labeling on vehicle-
control and pCPA-treated animals were analyzed by measuring
its optical density (OD) as previously described (Cordero et al.
2005). Images were taken rostral-caudally and mean optical
density was visualized using image analysis NIH-produced
software, ImageJ (http://rsb.info.nih.gov/nih.image/default.
html). The OD was calculated from a relative scale of
intensity. The calibration density was kept constant for
measuring all sections to avoid experimental variances. Non-
specific OD in sections was measured from the corpus
callosum, these density values were used as background.
SERT density of each area was measured independently and a
single measurement was obtained from every area in each
hemisphere. Measurement of mean density was taken and
averaged, after background subtraction, from each area in both
the left and the right hemisphere of each slice. The results are
shown as SERT optical density (OD/pixel).
Drugs
The following drugs were used in this study: 4-chloro-DL-
phenylalanine methyl ester hydrochloride (pCPA), (±)-8-
Hydroxy-2-(dipropylamino) tetralin hydrobromide (8-OH-
DPAT), WAY 100635 and Ro 60-0175 from Sigma-Aldrich
Química (Spain); methiothepin maleate, SB 242084 from
Tocris Bioscience (Spain); and fluoxetine from Biotrend
(Germany). For systemic administration, 8-OH-DPAT, WAY
100635, methiothepin maleate, and pCPA were prepared in
physiological saline (NaCl 0.9 %); SB 242084 was prepared
in physiological saline containing 8 % hydroxypropyl-β-
cyclodextrin; Ro 60-0175, fluoxetine and urethane were pre-
pared in distilled water. For local administration, 8-OH-DPAT,
Ro 60-0175, and WAY 100635 were dissolved in Dulbecco’s
buffered saline solution. SB 242084 was dissolved in
Dulbecco’s buffered saline solution containing 8 %
hydroxypropyl-β-cyclodextrin.With the exception of urethane,
drugs were freshly prepared prior to immediate use.
Statistical analysis of data
Experimental data were analyzed using the computer program
GraphPad Prism (v. 5.01, GraphPad Software, Inc). The elec-
trophysiological and neurochemical data were analyzed by
unpaired Student’s t test, one-way analysis of variance
(ANOVA) or Fisher’s exact test for the comparison of the
number of cells with burst firing activity. The effect of the
different drugs on the electrophysiological parameters was
analyzed by one-way ANOVA (when some data were miss-
ing) or repeated measures (RM) one-way and RM two-way
ANOVA. For behavioral experiments, RM two-way ANOVA
were used. All significant ANOVAs were followed by
Bonferroni’s post hoc test. The level of statistical significance
was set at p <0.05. Data are presented as the group mean ±
standard error of the mean (SEM).
Results
Effect of the pCPA treatment, the fluoxetine treatment,
and the non-selective serotonergic receptor antagonist
administration on STN
Three hundred and ninety-one neuronswere recorded in the STN
24 h after the last vehicle, pCPA (300 mg/kg, i.p. for 3 days) or
fluoxetine (10 mg/kg, i.p. for 14 days) injection: 176 neurons
from 41 vehicle-treated control rats, 85 neurons from 16 pCPA-
treated rats, and 130 neurons from 17 fluoxetine-treated rats. All
cells were located within the STN and showed a biphasic wave-
form with a duration of 1.0–1.5 ms.
As shown in Fig. 1a, the mean basal firing rate of STN
neurons was significantly higher after 5-HT depletion (firing
rate=7.48±0.50 Hz for the vehicle-treated control vs. 10.26±
0.60 Hz for the pCPA-treated group; p <0.001, unpaired
Student’s t test), whereas it remained unchanged after
prolonged treatment with fluoxetine (firing rate=7.33±
0.62 Hz for the vehicle-treated, and 7.70±0.55 Hz for the
fluoxetine-treated group; p >0.05, unpaired Student’s t test).
No differences were found in the coefficient of variation of the
recorded STN neurons from the different groups (Fig. 1b).
However, 5-HT depletion also modified the firing pattern of
STN neurons, increasing the relative amount of STN neurons
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that exhibited bursting firing pattern comparing to its control
group (53.65 % in pCPA-treated rats vs. 29.31 % in vehicle-
treated control rats; p <0.01, Fisher’s exact test; Fig. 1c).
Finally, no differences in the firing pattern between vehicle
and fluoxetine-treated groups were observed (Fig. 1c).
On the other hand, pCPA treatment reduced the concentra-
tions of 5-HT in the STN (F (2,14)=27.51, p<0.001, one-way
ANOVA) and of the main 5-HT metabolite, 5-HIAA (F (2,14)=
58.14, p<0.001, one-way ANOVA; Fig. 1d). The levels of DA
were not modified in any of the experimental groups
(F (2,14)=0.09, p>0.05, one-way ANOVA). Immunostaining ex-
periments showed no difference in the density of SERT between
vehicle-control and pCPA-treated rats in dorsal raphe nucleus
target areas (prefrontal cortex and hippocampus), neither in the
STN (Figure S3A, B).
Finally, the intravascular administration of the non-
selective serotonergic receptor antagonist, methiothepin (25–
1,000 μg/kg, i.v., n =9) did not produce any significant mod-
ification in the firing rate (F (6, 43)=0.353, p> 0.05, one-way
ANOVA), nor in the coefficient of variation (F (6,43)=0.693,
p> 0.05 one-way ANOVA) of STN neurons in control rats
(Table 1). However, methiothepin administration increased
the number of neurons exhibiting a bursting firing pat-
tern (p <0.001, Fisher’s exact test; Table 1).
Effect of 5-HT1A serotonergic drugs on STN neuron activity
in control and pCPA-treated rats
Systemic administration of cumulative doses of the selective
5-HT1A agonist, 8-OH-DPAT (10–100 μg/kg, i.v., n =8) did
not change the firing rate of STN neurons or the coefficient of
variation in vehicle-control group rats (Fig. 2a, b). However,
in pCPA-treated rats, 8-OH-DPAT reduced, in a dose-
dependent manner, the firing rate by 30 % (F (5,35)=5.961,
p <0.001, RM one-way ANOVA) and increased the coeffi-
cient of variation by 44 % (F (5,35)=4.255, p <0.01, RM one-
way ANOVA; Fig. 2a, b). This effect was reversed by the
5-HT1A antagonist, WAY 100635 (100 μg/kg, i.v., n =8;
Fig. 2a, b). No effect on the firing pattern of STN neurons
was observed after 8-OH-DPAT administration in either
vehicle- or pCPA-treated groups (p >0.05, Fisher’s exact test).
Next, 8-OH-DPAT (20–160 fmol) applied directly into the
STN caused a marked inhibition of STN neuron activity in
vehicle-control animals [maximal reduction of the firing rate
was 62 % of the basal value (F (4,42)=17.85, p <0.001, one-
way ANOVA; Fig. 2c, e)], and in pCPA-treated animals
[maximal reduction of the firing rate was 60 % of the basal
value (F (4,119)=30.46, p <0.001, one-way ANOVA;
Fig. 2d, e)]. This inhibitory effect of 8-OH-DPAT (20–
Fig. 1 STN neuron electrophysiological parameters and 5-HT, 5-HIAA,
and DA levels in the STN. Firing rate, coefficient of variation, and firing
pattern (a , b , and c , respectively) of neurons recorded 24 h after the last
vehicle, pCPA (300 mg/kg/day, i.p. 3 days) or fluoxetine (10 mg/kg/day,
i.p. 14 days) injection; 86 neurons from 25 vehicle-control rats, 85
neurons from 16 pCPA-treated rats, 90 neurons from 16 vehicle-treated
rats, and 130 neurons from 17 fluoxetine-treated rats. d Effect of pCPA
(300 mg/kg/day, i.p., 3 days) and fluoxetine (10 mg/kg/day, i.p., 14 days)
treatments on 5-HT, 5-HIAA, and DA levels in the STN, in control
(n =6), pCPA-treated (n=5), and fluoxetine-treated (n =6) animals. Each
value represents the mean ± SEM. ***p <0.001 vs. its control group
(unpaired Student’s t test). ##p <0.01 vs. its control group (Fisher’s exact
test). &&&p <0.001 vs. control group (Bonferroni’s post hoc test)
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160 fmol) was blocked by the previous systemic administra-
tion of WAY 100635 (100 μg/kg, i.v), in both vehicle-control
(n =10) and pCPA-treated (n =5) rats (Fig. 2f).
Finally, WAY 100635 did not modify the firing rate or the
coefficient of variation of STN neurons, neither when WAY
100635 was administrated systemically (6.25–100 μg/kg, i.v.,
n =7; Table 1) nor when it was locally applied into the STN
(20–320 fmol, n =51 neurons from eight rats) (Figure S1A).
However, the intravascular administration of cumulative
doses of WAY 100635 enhanced the amount of STN neurons
that exhibited a bursting firing pattern (p< 0.001, Fisher’s
exact test; Table 1). After pCPA treatment WAY 100635 did
not elicit any effect on STN neuron activity (data not shown).
Effect of 5-HT2C serotonergic drugs on STN neuron activity
in control and pCPA-treated rats
The administration of cumulative doses of the 5-HT2C agonist,
Ro 60-0175 (20–320 μg/kg, i.v.), did not affect the firing param-
eters of STN neurons in vehicle- (n=6) or pCPA-treated rats
(n=8; Fig. 3a, b). However, as shown in Fig. 3c and d, local
application of Ro 60-0175 (80–320 pmol) into the STN mark-
edly stimulated the recorded neurons from vehicle-control ani-
mals [maximal increment of the firing rate was 113 % of the
basal value (F (3,33)=4.49, p<0.01, one-wayANOVA)] and from
pCPA-treated animals [maximal increment of the firing rate was
95 % of the basal value (F (3,116)=11.23, p<0.001, one-way
ANOVA)]. Additionally, the systemic administration of the 5-
HT2C antagonist, SB 242084 (200 μg/kg, i.v.) prior to the local
application of Ro 60-0175 into the STN blocked the stimulatory
effect of the 5-HT2C receptor agonist, both in vehicle-control
(n=11) and in pCPA-treated (n=7) rats (Fig. 3f).
The systemic administration of SB 242084 (12.5–200
μg/kg, i.v.; n =6), did not modify any firing parameter of
STN neurons in control rats (Table 1). Moreover, the local
application of SB 242084 (200–3,200 fmol, n =34 neurons
from five rats) into the STN neither changed the firing rate in
control rats (Figure S1B). After pCPA treatment SB 242084
did not elicit any effect on STN neuron activity (data not
shown).
Effect of fluoxetine treatment on STN neuron response
to fluoxetine, 5HT1A, and 5HT2C agonists and motor behavior
In vehicle-treated control rats, the acute administration of
fluoxetine (2.5–10 mg/kg, i.v.; n =14) did not induce any
change in STN activity (Fig. 4a). However, after 14 days of
treatment with fluoxetine (10 mg/kg every 24 h, i.p.), a chal-
lenge of fluoxetine (n =8) produced a significant increase of
53 % of the firing rate (F (3,21)=9.141, p <0.001, RM one-way
ANOVA; Fig. 4a), while the coefficient of variation (54.64±
6.68 % basal condition vs. 44.24±2.24 % after 10 mg/kg
Table 1 Effects of systemic ad-
ministration of cumulative doses
of the non-specific 5-HT antago-
nist, methiothepin (n =9 neurons
from nine rats), the 5-HT1A
antagonist, WAY 100635
(n =7 neurons from seven rats),
and the 5-HT2C antagonist, SB
242084 (n =6 neurons from six
rats) on STN neuron activity in
control rats
Data from the firing rate and the
coefficient of variation (CV) are
expressed as means ± SEM of the
percentage of the basal condition.
The firing pattern is presented as
percentage of neurons which
represent the standard discharge
patterns of STN neurons
***p <0.001 vs. basal condition
(Fisher’s exact test)
Drug Dose (μg/kg, i.v.) Firing rate (%) CV (%) Firing pattern (%)
Tonic Random Bursting
Methiothepin 0 100 100 55.6 11.1 33.3
25 110.1±11.97 105.3±10.18 22.2 0 77.8***
50 120.2±17.40 114.9±13.50 33.3 11.1 55.6***
100 118.2±19.11 123.4±16.39 55.6 11.1 33.3
200 132.7±17.91 117.4±13.61 22.2 11.1 66.7***
400 111.3±7.75 146.8±12.53 22.2 11.1 66.7***
1,000 126.7±22.89 135.2±58.28 22.2 11.1 66.6***
WAY 100635 0 100 100 42.9 14.2 42.9
6.25 87.6±9.7 107.9±9.9 14.2 14.2 71.6***
12.5 90.0±14.1 104.4±11.7 14.3 0 85.7***
25 99.1±18.6 108.4±17.4 0 0 100***
50 104.3±17.5 114.6±16.4 14.3 0 85.7***
75 106.8±18.7 114.1±17.7 14.3 0 85.7***
100 114.9±20.1 107.7±16.7 42.9 14.2 42.9
SB 242084 0 100 100 83.3 0 16.7
12.5 98.9±1.0 100.6±3.3 66.7 0 33.3
25 102.3±3.5 100.0±3.3 83.3 0 16.7
50 101.5±3.4 105±6.3 66.7 0 33.3
100 108.2±9.2 106.2±5.4 66.7 0 33.3
150 106.0±7.7 102.5±7.2 83.3 0 16.7
200 106.9±9.1 103.0±9.8 66.7 0 33.3
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dose) and the firing pattern (44.0 % of bursting neurons in
basal condition vs. 35.5 % of bursting neurons after 10 mg/kg
dose) remained unaltered. The fluoxetine treatment did not
change the inhibitory effect induced on STN neurons by the
local application into the STN of the 5-HT1A receptor agonist,
8-OH-DPAT (20–160 fmol, n =29 neurons from nine rats)
(F (1,208)=0.71, p> 0.05, two-way ANOVA; Fig. 4b), nor the
excitatory effect induced by the 5-HT2C receptor agonist, Ro
60-0175 (40–320 pmol, n=35 neurons from nine rats; F (1,202)=
0.52, p> 0.05, two-way ANOVA; Fig. 4c).
Finally, the bar test and the rotarod test were performed to
analyze if the fluoxetine treatment induced motor impair-
ments. Fluoxetine treatment did not produce any modification
in the rotarod test (Figure S2A). However, on the course of the
chronic treatment, fluoxetine-treated animals showed marked
catalepsy in comparison to the vehicle-injected group both 30
(F (1,42)=10.84, p< 0.01, RM two-way ANOVA) and 60 min
after the administration (F (1,42)=7.62, p< 0.05, RM two-way
ANOVA). On day 14, rats in the fluoxetine-treated group
remained significantly longer time on the bar (for statistical
Fig. 2 Effect of 8-OH-DPAT on STN neuron activity. 8-OH-DPAT (10–
100 μg/kg, i.v.) induced an inhibition in the firing rate (a) and an increase
in the coefficient of variation (b) in pCPA-treated (300 mg/kg/day, i.p.
3 days) rats (black circles ; n =8 neurons from eight rats). This effect was
reverted by administration of the 5-HT1A antagonist, WAY 100635
(0.1 mg/kg, i.v.). In vehicle-control rats (white circles; n=8 neurons from
eight rats), firing rate, and coefficient of variation remained unaltered
(a and b). c When 8-OH-DPAT (20–160 fmol) was locally applied into
the STN (white square ; n =12 neurons from seven vehicle-control rats) an
inhibitory effect was induced. The systemic administration of WAY
100635 (0.1 mg/kg, i.v.) prior to the local application of 8-OH-DPAT
blocked the inhibitory effect of the 5-HT1A receptor agonist (black
triangle ; n =11 neurons from 11 vehicle-control rats). d 8-OH-DPAT
(20–160 fmol) locally applied into the STN of pCPA-treated animals
(white square ; n=26 neurons from five pCPA-treated rats) caused an
inhibitory effect. The systemic administration of WAY 100635 (0.1
mg/kg, i.v.) prior to the local application of 8-OH-DPAT blocked the
inhibitory effect of the 5-HT1A receptor agonist (black triangle; n =5
neurons from five pCPA-treated rats). e Representative firing rate histo-
gram illustrating the inhibitory effect of local administration of 8-OH-
DPAT on STN neuronal activity. f Representative firing rate histogram
illustrating WAY 100635 induced blockage of the inhibitory effect of
local administration of 8-OH-DPAT on STN neuron activity. *p <0.05
and ***p<0.001 vs. basal firing rate (Bonferroni’s post hoc test)
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details see Fig. 4d). In agreement with other authors (Gutierrez
et al. 2002), fluoxetine chronic treatment had an anorexigenic
effect and rats belonging to that group showed reduction of
body weight in comparison to the vehicle-treated control rats
(Figure S2B).
Discussion
The results of the present study show that 5-HT depletion as
well as systemic administration of either a non-selective sero-
tonergic receptor antagonist or a 5-HT1A receptor antagonist
Fig. 3 Effect of Ro 60-0175 on STN neuron activity. Intravenous ad-
ministration of Ro 60-0175 (20–320 μg/kg) did not induce any effect on
the firing rate (a) or on the coefficient of variation (b) either in pCPA-
(300 mg/kg/day, i.p. 3 days; black circle; n =8 neurons from eight rats) or
vehicle-treated rats (white circle; n =6 neurons from six rats). c When Ro
60-0175 (80–320 pmol) was locally applied into the STN (white square ;
n =11 neurons from five vehicle-control rats) a stimulatory effect was
induced. The systemic administration of SB 242084 (0.2 mg/kg, i.v.)
prior to the local application of Ro 60-0175 blocked the stimulatory effect
of the 5-HT2C receptor agonist (black triangle ; n =14 neurons from 14
vehicle-control rats). d Ro 60-0175 locally applied into the STN of
pCPA-treated animals (white square ; n=36 neurons from seven pCPA-
treated rats) caused a stimulatory effect. The systemic administration of
SB 242084 (0.2 mg/kg, i.v.) prior to the local application of Ro 60-0175
blocked the stimulatory effect of the 5-HT2C receptor agonist (black
triangle ; n=7 neurons from seven pCPA-treated rats). e Representative
firing rate histogram illustrating the stimulatory effect of local adminis-
tration of Ro 60-0175 on STN neuronal activity. f Representative firing
rate histogram illustrating SB 242084 induced blockage of the
stimulatory effect of local administration of Ro 60-0175 on STN
neuron activity. *p <0.05 and ***p <0.001 vs. basal firing rate
(Bonferroni’s post hoc test)
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changed the firing pattern of STN neurons. Moreover, disrup-
tion of the endogenous serotonergic tonic control results in an
increment of STN neuron activity. Local activation of 5-HT1A
and 5-HT2C receptors leads to opposite effects, i.e., inhibition
and stimulation, on STN neuron activity. Finally, the 5-HT1A-
mediated effect depends on the tissue 5-HT content and
prolonged 5-HT reuptake inhibition enhances STN neuronal
response to fluoxetine but induces cataleptic behavior in rats.
The main serotonergic modulation of STN activity arises
from the dorsal raphe nucleus, which imposes a tonic inhibi-
tion of basal STN activity (Di Matteo et al. 2008). In agree-
ment with our results, lesioning the dorsal raphe nucleus with
5,7-dihydroxytryptamine results in an increase in the firing
rate and in the number of bursting neurons in the STN
in rats (Liu et al. 2007). In addition to the direct serotonergic
control from the dorsal raphe nucleus, indirect serotonergic
mechanisms may also control STN activity, since several
nuclei projecting to the STN are regulated by 5-HT and
express serotonergic receptors (Huot et al. 2011; Liu et al.
2007).
In the present study, we observed that after 5-HT depletion,
but not in control conditions, systemic administration of the
selective 5-HT1A agonist, 8-OH-DPAT, inhibited STN neuron
activity. This finding may be attributed to the availability of 5-
HT, since no changes in the sensitivity of 5-HT1A receptors to
8-OH-DPAT have been reported after pCPA treatment (Eide
et al. 1988). Moreover, when 8-OH-DPATwas applied direct-
ly into the STN, it produced a larger inhibition than that
observed by systemic administration. This inhibitory effect
was mediated by 5-HT1A receptors as it was reversed or
blocked by systemic administration of the selective 5-HT1A
receptor antagonist, WAY 100635. Altogether, these results
Fig. 4 Effect of fluoxetine on STN neuron activity and motor behavior
in vehicle- and chronic fluoxetine-treated (10 mg/kg/day, i.p. 14 days)
rats. a Cumulative doses of fluoxetine (2.5–10 mg/kg, i.v.) induced an
increase in the firing rate in fluoxetine-treated rats (black circle ; n =8
neurons from eight fluoxetine-treated rats), but not in the vehicle-treated
rats (white circle ; n =14 neurons from 14 vehicle-treated control rats).
The fluoxetine treatment did not modify the inhibitory (b ) and the
excitatory (c) effects induced by the local application of 8-OH-DPAT
(20–160 fmol) or Ro 60-0175 (40–320 pmol) into the STN, respectively.
d Fluoxetine chronic administration induced catalepsy on day 14 after the
beginning of the treatment. Note that no catalepsy was observed before
fluoxetine administration or at any time in the vehicle-treated group.
Eight animals were included in each group. ^p <0.05 vs. basal firing rate;
##p< 0.01 and ###p <0.001 vs. respective vehicle-treated group;
***p< 0.001 vs. respective first day; ££p< 0.01 vs. respective fifth day;
&&p< 0.01 and &&&p< 0.001 vs. respective ninth day (Bonferroni’s
post hoc test)
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indicate that the effect of 8-OH-DPAT on the STN involves
direct and indirect mechanisms: (1) a direct effect mediated by
the activation of postsynaptic 5-HT1A receptors on STN neu-
rons that results in the inhibition of STN neurons, as it is
suggested by in vitro experiments (Shen et al. 2007;
Stanford et al. 2005) and (2) an indirect effect by activating
5-HT1A receptors on the dorsal raphe nucleus (that reduces the
release of 5-HT) and areas that project to the STN. The
activation of serotonergic receptors on those nuclei may hide
the direct inhibitory effect mediated by 5-HT1A receptors on
STN neurons.
Systemic administration of the 5-HT2C agonist Ro 60-0175
did not modify STN activity in control conditions or after 5-HT
depletion, while local application stimulated STN neurons. This
stimulation was blocked by systemic administration of the
selective 5-HT2C receptor antagonist SB 242084. Although
these results agree with in vitro studies, where 5-HT2C receptors
has been proposed to mediate stimulation of STN neurons
(Shen et al. 2007; Stanford et al. 2005), they differ from those
published by Zhang et al. (2009), where an increase in the firing
rate of STN neurons was reported after systemic administration
of a non-selective 5-HT2C agonist. The discrepancies with the
latter publication may reflect the different selectivity of the
applied drugs and highlight the importance of using specific
drugs. Our results suggest that 5-HT2C receptors located in the
STN, and in other brain areas, are implicated in the modulation
of neuronal firing rate, as it has been described in other BG
nuclei (Beyeler et al. 2010; Invernizzi et al. 2007). As also
mentioned for 5-HT1A receptors, the activation of 5-HT2C
located outside the STN may blunt the direct effect of the 5-
HT2C receptor agonist when it is systemically applied.
We observed that chronic fluoxetine treatment did not
change the spontaneous activity of STN neurons or the basal
5-HT levels in this nucleus, but it enhanced the sensitivity to
fluoxetine. In line with this, using microdialysis techniques,
Dawson et al. (2000, 2002) have shown that chronic fluoxe-
tine treatment increases extracellular 5-HT in response to a
fluoxetine challenge, despite not altering basal 5-HT levels in
the frontal cortex. We also found that chronic fluoxetine
treatment did not modify the effect of local application of 5-
HT1A and 5-HT2C receptor agonists in the STN. This suggests
that chronic fluoxetine treatment does not change the sensi-
tivity of postsynaptic 5-HT1A and 5-HT2C receptors in STN
neurons, as it has been proposed for other brain areas (Le Poul
et al. 2000). In contrast, other authors have described a desen-
sitization of somatodendritic 5-HT1A receptors after fluoxe-
tine treatment (Blier and de Montigny 1994; Dawson et al.
2000, 2002; Le Poul et al. 2000; Rainer et al. 2012). Freo et al.
(2010) have pointed that chronic fluoxetine administration
reduces and increases the response mediated by 5-HT1A and
5-HT2A/2C receptors, respectively. These effects are not ho-
mogeneous through the brain, being observed in some areas
but not in others. As mentioned before, the enhancement of
STN neuron activity induced by systemic fluoxetine adminis-
tration in fluoxetine-treated rats could be a consequence of
effects in other brain areas. In fact, an acute challenge of
fluoxetine in chronically treated animals gives rise to in-
creased extracellular 5-HT levels in the frontal cortex
(Dawson et al. 2000, 2002) and reduced DA levels in the
dorsal striatum (Morelli et al. 2011). Given that these areas
influence STN activity, such changes in neurotransmitter con-
centrations may be related to the electrophysiological changes
observed in the STN and in motor behavior.
Using behavioral approaches, we found that chronic fluox-
etine treatment did not impair motor coordination and balance
in rats, although it induced catalepsy. Other authors have
reported that acute fluoxetine administration potentiates
haloperidol-induced catalepsy (Tatara et al. 2012) and that
the STN is implicated in cataleptic behavior (Zadow and
Schmidt 1994). According to the widely accepted BG func-
tional model (Alexander et al. 1986), increased STN neuron
activity results in an enhancement of BG output nuclei signal
leading to movement inhibition and therefore, movement
disorders (Hamani et al. 2004). Hence, we speculate that the
increment in STN activity is involved in the extrapyramidal
side effects induced by fluoxetine.
In conclusion, this study shows that 5-HT modifies STN
neuron activity through direct and indirect mechanisms. Our
results contribute to clarify the role of serotonergic neurotrans-
mission in STN neuron activity and understanding the mech-
anisms underlying the extrapyramidal side effects induced by
SSRIs.
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